³í¹®) Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in 1 women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multi-2 center, single-arm phase II study OPEB-01/APGOT-OV4
¿¬¼¼¾Ïº´¿ø ºÎÀξϼ¾ÅÍ ÀÌÁ¤À±, ±è»ó¿î ±³¼ö, ±èÀ¯³ª °»ç ¿¬±¸ÆÀ